Recent Updates
Recently added Catalysts

GSK4382276A Dose level 1

Phase 1

Influenza, Human | Monoclonal antibody | Infectious Disease |GSK plc|Last Updated: Mar 10, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials1
Total Enrollment324
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT05446740A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older AdultsPHASE1 COMPLETED 324Aug 9, 2022Mar 26, 2024Mar 10, 20267 Belgium, Canada +1
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants Reporting Any Solicited Administration Site Events
Day 1 to Day 7

Assessed solicited administration site events included pain, erythema/redness, swelling and Lymphadenopathy (defined as localized axillary, cervical or supraclavicular swelling or tenderness ipsilateral to the injection arm). Any = occurrence of the event regardless of intensity grade.

Number of Participants Reporting Any Solicited Systemic Events
Day 1 to Day 7

Assessed solicited systemic events included fever, chills, headache, myalgia, arthralgia and fatigue. Any = occurrence of the symptom regardless of intensity grade.

Number of Participants Reporting Any Unsolicited Adverse Events (AEs)
Day 1 to Day 28

An unsolicited AEs is an AEs that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow up for solicited events. Unsolicited AEs must have been communicated by a participant who has signed the informed consent or through his/her caregiver. Unsolicited AEs include both serious and non-serious AEs. Any = occurrence of the symptom regardless of intensity grade or relation to study vaccination.

Number of Participants Reporting Serious Adverse Events (SAEs)
Day 1 to Day 183

An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect in the offspring of a study participant, or resulted in abnormal pregnancy outcomes, or in other situations that were considered serious per medical or scientific judgment.

Number of Participants Reporting AEs of Special Interest (AESIs)
Day 1 to Day 183

The following events were considered as AESI in this study: severe hypersensitivity reactions within 24 hours after study intervention administration, myocarditis/pericarditis and potential immune-mediated diseases (pIMDs).

Number of Participants Reporting Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 8 for Hematology, Clinical Chemistry, Coagulation and Urine Analysis
At Day 8 compared to baseline (Day 1)

Clinically significant abnormal laboratory findings are those which are not associated with an underlying disease, unless judged by the investigator to be more severe than expected for the participants condition. Normal or missing values refer to laboratory values that were within normal range or missing at baseline.

Number of Participants Reporting Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 29 for Hematology,Clinical Chemistry, Coagulation and Urine Analysis
At Day 29 compared to baseline (Day 1)

Clinically significant abnormal laboratory findings are those which are not associated with an underlying disease, unless judged by the investigator to be more severe than expected for the participants condition. Normal or missing values refer to laboratory values that were within normal range or missing at baseline.

Geometric Mean Titers (GMT) of Anti-vaccine Antibody Titers
At Day 1
GMT of Anti-vaccine Antibody Titers
At Day 22
Geometric Mean Increase (GMI) of Anti-vaccine Antibody Titers From Day 1 (Baseline) to Day 22
From Day 1 to Day 22

GMI is defined as the geometric mean of the ratios of the post-dose anti-vaccine antibody titers over the Day 1 anti-vaccine antibody titers.

Percentage of Participants With Anti-vaccine Antibody Seroconversion Rate (SCR)
From Day 1 to Day 22

SCR is defined as the percentage of dosed participants who have either an anti-vaccine antibody pre-dose titer \< 1:10 and a post-dose anti-vaccine antibody titer ≥ 1:40 or a pre-dose anti-vaccine antibody titer ≥ 1:10 and at least a 4-fold increase in post-dose anti-vaccine antibody titer.

Percentage of Participants With Anti-vaccine Antibody Seroprotection Rate (SPR)
At Day 22

SPR is defined as the percentage of dosed participants with a anti-vaccine antibody titer ≥ 1:40.

Secondary Endpoints
GMT of Anti-vaccine Antibody Titers
At Day 62 and Day 183
GMI of Anti-vaccine Antibody Titers From Day 1 (Baseline) to Day 62
From Day 1 to Day 62
GMI of Anti-vaccine Antibody Titers From Day 1 (Baseline) to Day 183
From Day 1 to Day 183
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelSEQUENTIAL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
Flu mRNA_Dose level 1_Younger adults (YA)EXPERIMENTALOn Day 1, YA adult participants received Flu mRNA at Dose Level 1, the lowest concentration evaluated in the study.
Flu mRNA_Dose level 2 _YAEXPERIMENTALOn Day 1, YA participants received Flu mRNA at Dose Level 2, which corresponds to a higher concentration than Dose Level 1.
Flu mRNA_Dose level 3_YAEXPERIMENTALOn Day 1, YA participants received Flu mRNA at Dose Level 3, which corresponds to a higher concentration than Dose Level 2.
Flu mRNA_Dose level 4_YAEXPERIMENTALOn Day 1, YA participants received Flu mRNA at Dose Level 4, which corresponds to a higher concentration than Dose Level 3.
Flu mRNA_Dose level 5_YAEXPERIMENTALOn Day 1, YA participants received Flu mRNA at Dose Level 5, which corresponds to a higher concentration than Dose Level 4.
Flu mRNA_Dose level 6_YAEXPERIMENTALOn Day 1, YA participants received Flu mRNA at Dose Level 6, which corresponds to a higher concentration than Dose Level 5.
Flu mRNA_Dose level 7_YAEXPERIMENTALOn Day 1, YA participants received Flu mRNA at Dose Level 7, which corresponds to a higher concentration than Dose Level 6.
Flu mRNA_ Dose level 8_YAEXPERIMENTALOn Day 1, YA participants received Flu mRNA at Dose Level 8, which corresponds to a higher concentration than Dose Level 7.
Flu mRNA_Dose level 9_YAEXPERIMENTALOn Day 1, YA participants received Flu mRNA at Dose Level 9, which corresponds to a higher concentration than Dose Level 8.
Flu mRNA_Dose level 10_YAEXPERIMENTALOn Day 1, YA participants received Flu mRNA at Dose Level 10, the highest concentration evaluated in the study.
Pooled Control_YAACTIVE_COMPARATOROn Day 1, YA participants received a single dose of FDQ21A - NH or FDQ22A -NH administered as a control and were analyzed together as pooled group throughout the study.
Flu mRNA_Dose level 7_Older adults (OA)EXPERIMENTALOn Day 1, OA participants received Flu mRNA at Dose Level 7.
Control_OAACTIVE_COMPARATOROn Day 1, OA participants received a single dose of FDQ21A-NH administered at as a control.
Interventions
NameTypeDescription
GSK4382276A Dose level 1BIOLOGICALSingle dose of intervention administered at Day 1
GSK4382276A Dose level 2BIOLOGICALSingle dose of intervention administered at Day 1
GSK4382276A Dose level 3BIOLOGICALSingle dose of intervention administered at Day 1
GSK4382276A Dose level 4BIOLOGICALSingle dose of intervention administered at Day 1
GSK4382276A Dose level 5BIOLOGICALSingle dose of intervention administered at Day 1
GSK4382276A Dose level 6BIOLOGICALSingle dose of intervention administered at Day 1
GSK4382276A Dose level 7BIOLOGICALSingle dose of intervention administered at Day 1
GSK4382276A Dose level 8BIOLOGICALSingle dose of intervention administered at Day 1
GSK4382276A Dose level 9BIOLOGICALSingle dose of intervention administered at Day 1
GSK4382276A Dose level 10BIOLOGICALSingle dose of intervention administered at Day 1
FDQ21A-NHCOMBINATION_PRODUCTSingle dose of intervention administered at Day 1
FDQ22A-NHCOMBINATION_PRODUCTSingle dose of intervention administered at Day 1
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 80 Years
SexALL
Healthy VolunteersYes
Study Sites7

Inclusion Criteria: * A male or female between and including 18 and 45 years of age (YAs) or between and including 60 and 80 years of age (OAs) at the time of the study intervention administration. The age of sentinel participants in OA category will be limited to maximum 70 years. * Healthy or med...

Countries:BelgiumCanadaSpain
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
MEDIUMMay 21, 2026NCT05446740TRIAL_REMOVED: changed
MEDIUMMay 21, 2026NCT05446740TRIAL_REMOVED: changed